25+ Key Opinion Leaders (KOLs) were contacted for insights on Glucagon-like Peptide-1 (GLP-1) Agonists incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility
Multiple clinical trialsincluding SUSTAIN-6 (semaglutide) and REWIND (dulaglutide)showed significant reductions in major adverse cardiovascular events (MACE) such as: Heart attack Stroke Cardiovascular death This benefit appears to be independent of weight loss , suggesting direct protective effects on the arteries, blood pressure, and cholesterol metabolism
However, enhancing the endogenous secretion of GLP-1 through dietary, microbial, or pharmacological stimuli represents a promising complementary strategy
Some studies reported increased clinical pregnancy and live birth rates, though statistical power varied
Your healthcare provider can also help you decide which will be better for you
While these extras arent required, they can make a difference in your overall experience and outcomes